348 related articles for article (PubMed ID: 2150753)
1. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
2. Reversion and rereversion in ras-transformed cells.
Marshall CJ
Immunol Ser; 1990; 51():89-106. PubMed ID: 2128917
[No Abstract] [Full Text] [Related]
3. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
4. Reversion of middle T antigen-transformed Rat-2 cells by Krev-1: implications for the role of p21c-ras in polyomavirus-mediated transformation.
Jelinek MA; Hassell JA
Oncogene; 1992 Sep; 7(9):1687-98. PubMed ID: 1380149
[TBL] [Abstract][Full Text] [Related]
5. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes.
Stacey DW; Roudebush M; Day R; Mosser SD; Gibbs JB; Feig LA
Oncogene; 1991 Dec; 6(12):2297-304. PubMed ID: 1766676
[TBL] [Abstract][Full Text] [Related]
6. The interplay between ras oncogenes and tumor suppressor genes in experimental carcinogenesis.
Balmain A; Brown K; Bremner R
Immunol Ser; 1990; 51():75-88. PubMed ID: 2128916
[No Abstract] [Full Text] [Related]
7. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
[TBL] [Abstract][Full Text] [Related]
8. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
9. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
Velasco JA; Avila MA; Notario V
Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
Yokoyama T
Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
[TBL] [Abstract][Full Text] [Related]
11. Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant.
Ogiso Y; Yokoyama T; Watari H; Shih TY; Kuzumaki N
Exp Cell Res; 1993 Oct; 208(2):415-21. PubMed ID: 7690710
[TBL] [Abstract][Full Text] [Related]
12. Isolation of azatyrosine-induced revertants from ras-transformed human mammary epithelial cells.
Kyprianou N; Taylor-Papadimitriou J
Oncogene; 1992 Jan; 7(1):57-63. PubMed ID: 1741165
[TBL] [Abstract][Full Text] [Related]
13. Transformation suppressor genes.
Noda M; Kitayama H; Kanazawa S; Murata S; Matsuzaki T; Ikawa Y
Princess Takamatsu Symp; 1989; 20():233-9. PubMed ID: 2518686
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
Saez R; Chan AM; Miki T; Aaronson SA
Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
[TBL] [Abstract][Full Text] [Related]
15. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene.
Takahashi C; Akiyama N; Matsuzaki T; Takai S; Kitayama H; Noda M
Oncogene; 1996 May; 12(10):2137-46. PubMed ID: 8668339
[TBL] [Abstract][Full Text] [Related]
17. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
Kuo ML; Chou YW; Chau YP; Huang TS
Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
[TBL] [Abstract][Full Text] [Related]
18. Critical role of Rho in cell transformation by oncogenic Ras.
Prendergast GC; Khosravi-Far R; Solski PA; Kurzawa H; Lebowitz PF; Der CJ
Oncogene; 1995 Jun; 10(12):2289-96. PubMed ID: 7784077
[TBL] [Abstract][Full Text] [Related]
19. Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.
Li W; Michieli P; Alimandi M; Lorenzi MV; Wu Y; Wang LH; Heidaran MA; Pierce JH
Oncogene; 1996 Aug; 13(4):731-7. PubMed ID: 8761294
[TBL] [Abstract][Full Text] [Related]
20. Reversion of Ras transformed cells by Ets transdominant mutants.
Wasylyk C; Maira SM; Sobieszczuk P; Wasylyk B
Oncogene; 1994 Dec; 9(12):3665-73. PubMed ID: 7970725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
